Stimulatory and entraining effect of melatonin on tuberoinfundibular dopaminergic neuron activity and inhibition on prolactin secretion.
The aims of the present study were to determine if melatonin exerts an effect on prolactin (PRL) secretion via the tuberoinfundibular dopaminergic (TIDA) neurons and if endogenous or exogenous melatonin has an entraining effect on the rhythmic changes of TIDA neuronal activity and PRL secretion. Melatonin given in the morning (10:00 h), dose- (0.01-1 mg/kg, ip) and time- (at 15 and 60 min, but not at 30 min) dependently stimulated TIDA neuronal activity in ovariectomized (OVX), estrogen-treated rats as determined by 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the median eminence (ME). Serum PRL was concurrently inhibited by the injection. Melatonin administered in the afternoon (15:00 h) was even more effective in stimulating the lowered TIDA neuronal activity and inhibiting the increased PRL level than that given in the morning (10:00 h). S-20098, a melatonin agonist was also effective in stimulating the TIDA neurons. In contrast, S-20928, a putative melatonin antagonist, while it had no effect by itself, blocked the effect of S-20098. Although S-20928 failed to prevent melatonin's effect on ME DOPAC levels, six interspaced injections of S-20928, from 18:00 to 01:30 h, significantly blocked the increase of ME DOPAC levels at 03:00 h, indicating that the endogenous melatonin may play a role. We further used rats that received daily injection of melatonin (1 mg/kg, ip) at 18:00 h for 10 days and found that the injection augmented basal TIDA neuronal activity at 11:00 h and blunted the afternoon PRL surge. In all, melatonin can have an inhibitory effect on PRL secretion by stimulating the TIDA neurons, and it may help to entrain the circadian rhythms of both TIDA neuronal activity and PRL secretion.
Chu
Y S
YS
Department of Physiology, School of Life Science, National Yang-Ming University, Taipei, Taiwan.
Shieh
K R
KR
Yuan
Z F
ZF
Pan
J T
JT
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D002940:Circadian Rhythm / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D007033:Hypothalamus, Middle / Q000187:drug effects / Q000502:physiology*; D008550:Melatonin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010052:Ovariectomy; D011388:Prolactin / Q000037:antagonists & inhibitors* / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D000081:Acetamides; D009281:Naphthalenes; D015102:3,4-Dihydroxyphenylacetic Acid; C084711:agomelatine; C106874:N-(2-(1-naphthalenyl)ethyl)cyclobutanecarboxamide; D011388:Prolactin; D008550:Melatonin